Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin + dapagliflozin vs sitagliptin added to metformin in adults with type 2 diabetes inadequately controlled on metformin
2014-001102-17Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin + dapagliflozin + metformin with Sitagliptin + metformin (2 arms). Primary endpoint: Change from baseline in HbA1c at week 26. Started Jan 2015; status: completed.
02
Drugs
saxagliptindapagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-001102-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001102-17.